RA0691

antibody from Oursmab

Targeting: SLC34A2 NAPI-3B

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0691

Provider

Oursmab

Product name

Lifastuzumab (Biosimilar Reference Antibody) (SLC34A2)

Antibody type

Monoclonal

Description

Lifastuzumab (also known as RG-7599 or DNIB0600A) is an investigational antibody-drug conjugate (ADC) developed by Genentech/Roche. It consists of a humanized monoclonal antibody targeting sodium-dependent phosphate transporter NaPi2b (SLC34A2), linked to a potent cytotoxic payload, monomethyl auristatin E (MMAE), via a protease-cleavable linker. Upon binding to NaPi2b on the surface of tumor cells, the ADC is internalized, and the linker is cleaved within lysosomes to release the microtubule-disrupting MMAE, leading to cell cycle arrest and apoptosis. It has been clinically evaluated primarily for the treatment of NaPi2b-expressing ovarian cancer and non-small cell lung cancer (NSCLC).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.